Cancer
Malignant Liver Neoplasm
CI-CAN-00003177Explore in graph →
Top-level908 active trials14 approved drugs17 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00003177Explore in graph →
Clinical trials
4,126 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (460)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01901692 | Sorafenib vs.TransArterial Chemoembolization Plus RadioTherapy in Hepatocellular Carcinoma With Macrovascular Invasion(START) | completed | Phase 2 / Phase 3 | 90 | Asan Medical CenterOTHER | 1 | Sep 18, 2017 | clinicaltrials |
| NCT02042443 | Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery(S1310) | completed | Phase 2 | 53 | National Cancer Institute (NCI)NIH |
| 1 |
| Sep 12, 2017 |
| clinicaltrials |
| NCT00881751 | Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer | completed | Phase 2 | 95 | Medical University of South CarolinaOTHER | 1 | Sep 11, 2017 | clinicaltrials |
| NCT03261791 | Adjuvant Therapy With Apatinib for HCC Patients With PVTT Who Underwent Radical Resection | unknown | Phase 2 | 30 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 25, 2017 | clinicaltrials |
| NCT02821533 | Chemoembolization for Hepatocellular Carcinoma | terminated | Phase 2 | 24 | Chinese University of Hong KongOTHER | 1 | Aug 22, 2017 | clinicaltrials |
| NCT02007954 | Doxorubicin-eluting LC Bead M1 for Patients With Hepatocellular Carcinoma(DEBDOX) | completed | Phase 2 | 24 | Yale UniversityOTHER | 1 | Aug 11, 2017 | clinicaltrials |
| NCT02767375 | Hepatic Arterial Infusion Chemotherapy(HAIC) for Hepatoma After Resection(HAICAT) | unknown | Phase 2 / Phase 3 | 192 | Peking University Cancer Hospital & InstituteOTHER | 1 | Aug 10, 2017 | clinicaltrials |
| NCT01375569 | TRC105 for Liver Cancer That Has Not Responded to Sorafenib | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Jul 28, 2017 | clinicaltrials |
| NCT02089633 | Pegylated Recombinant Human Arginase 1 in Combination With Oxaliplatin and Capecitabine for the Treatment of HCC(PACOX) | completed | Phase 2 | 17 | Bio-Cancer Treatment International LimitedINDUSTRY | 1 | Jul 28, 2017 | clinicaltrials |
| NCT00483405 | Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer(NRR) | completed | Phase 2 | 33 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jul 12, 2017 | clinicaltrials |
| NCT01639352 | Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma | completed | Phase 2 | 20 | Lynn FeunOTHER | 1 | Jul 12, 2017 | clinicaltrials |
| NCT03208335 | Recombinant Human Endostatin(Rh-endostatin) Combine With Radiotherapy in the Treatment of Hepatocellular Carcinoma(HCC) | unknown | Phase 2 | 61 | Chinese PLA General HospitalOTHER | 1 | Jul 5, 2017 | clinicaltrials |
| NCT00072514 | Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies | completed | Phase 2 | 55 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 29, 2017 | clinicaltrials |
| NCT00039078 | Radiolabeled Glass Beads (TheraSphere®) in Treating Patients With Primary Liver Cancer That Cannot Be Removed by Surgery | withdrawn | Phase 2 | 0 | Allan TsungOTHER | 1 | Jun 26, 2017 | clinicaltrials |
| NCT02829359 | Effects of Antiviral Therapy on HBV Reactivation(HBV-DNA(-)) | completed | Phase 2 / Phase 3 | 200 | Guangxi Medical UniversityOTHER | 0 | Jun 12, 2017 | clinicaltrials |
| NCT00787787 | Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer | terminated | Phase 2 | 41 | University of WashingtonOTHER | 1 | Jun 1, 2017 | clinicaltrials |
| NCT00118352 | Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 12 | Fred Hutchinson Cancer CenterOTHER | 2 | May 30, 2017 | clinicaltrials |
| NCT00376987 | Zinc Supplements in Lowering Cadmium Levels in Smokers | completed | Phase 2 | 61 | Wake Forest University Health SciencesOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT00534001 | Bupropion in Helping Adults Stop Smoking | completed | Phase 2 | 95 | Roswell Park Cancer InstituteOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT01798147 | Selective Internal Radiotherapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Cholangiocellular Carcinoma (CCC). | unknown | Phase 2 | 24 | Johannes Gutenberg University MainzOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT01427881 | Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies | completed | Phase 2 | 43 | Fred Hutchinson Cancer CenterOTHER | 1 | May 19, 2017 | clinicaltrials |
| NCT00049504 | Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer | completed | Phase 2 | 53 | Fred Hutchinson Cancer CenterOTHER | 1 | May 17, 2017 | clinicaltrials |
| NCT03114085 | Apatinib Combined With Capecitabine Compared With Apatinib Treat Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 170 | First Affiliated Hospital of Guangxi Medical UniversityOTHER | 0 | May 15, 2017 | clinicaltrials |
| NCT00524316 | Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | terminated | Phase 2 | 16 | Roswell Park Cancer InstituteOTHER | 1 | May 9, 2017 | clinicaltrials |
| NCT01379521 | Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC(TRACER) | terminated | Phase 2 | 65 | Novartis PharmaceuticalsINDUSTRY | 3 | May 3, 2017 | clinicaltrials |
| NCT02227914 | Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma | withdrawn | Phase 1 / Phase 2 | 0 | AmgenINDUSTRY | 1 | May 2, 2017 | clinicaltrials |
| NCT01357486 | Palliative Treatment of Hepatocellular Carcinoma in Patient With CHILD B Cirrhosis(PRODIGE 21) | completed | Phase 2 | 160 | University Hospital, BordeauxOTHER | 1 | May 1, 2017 | clinicaltrials |
| NCT00128596 | Arsenic Trioxide in Treating Patients With Metastatic Liver Cancer That Cannot Be Removed by Surgery | completed | Phase 2 | 25 | University of PittsburghOTHER | 1 | Apr 27, 2017 | clinicaltrials |
| NCT01171482 | Comparison Study of Sorafenib and 5-fluorouracil/Mitomycin for Metastatic Hepatocellular Carcinoma | terminated | Phase 2 | 5 | Seoul National University HospitalOTHER | 1 | Apr 26, 2017 | clinicaltrials |
| NCT03130712 | A Study of GPC3-targeted T Cells by Intratumor Injection for Advanced HCC (GPC3-CART) | unknown | Phase 1 / Phase 2 | 10 | Shanghai GeneChem Co., Ltd.INDUSTRY | 1 | Apr 26, 2017 | clinicaltrials |
| NCT02725996 | By Using Adoptive Transfer of Autologous NK Cells to Prevent Recurrence of Hepatocellular Carcinoma After Curative Therapy | unknown | Phase 2 | 140 | Southwest Hospital, ChinaOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT02997956 | Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE) | withdrawn | Phase 1 / Phase 2 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT03124498 | A Study to Evaluate Autologous CIK Cells in Patients With Hepatocellular Carcinoma After TACE, PEIT or RFA | unknown | Phase 1 / Phase 2 | 55 | Chuan An Biotechnology Co., Ltd.INDUSTRY | 0 | Apr 21, 2017 | clinicaltrials |
| NCT02819869 | The Combination Effect of Statin Plus Metformin on Relapse-free | terminated | Phase 2 | 3 | Taipei Medical University WanFang HospitalOTHER | 1 | Apr 19, 2017 | clinicaltrials |
| NCT03026803 | A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer | terminated | Phase 2 | 4 | City of Hope Medical CenterOTHER | 1 | Apr 13, 2017 | clinicaltrials |
| NCT02261844 | Resveratrol and Human Hepatocyte Function in Cancer | withdrawn | Phase 1 / Phase 2 | 0 | University of LouisvilleOTHER | 1 | Mar 30, 2017 | clinicaltrials |
| NCT01125800 | A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB | completed | Phase 1 / Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 6 | Mar 20, 2017 | clinicaltrials |
| NCT03084380 | Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC) | unknown | Phase 1 / Phase 2 | 20 | Xinqiao Hospital of ChongqingOTHER | 1 | Mar 20, 2017 | clinicaltrials |
| NCT00322361 | Modified Process Hepatitis B Vaccine in Healthy Neonates (V232-056) | completed | Phase 2 | 566 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 16, 2017 | clinicaltrials |
| NCT01522937 | A Study of Individualized Stereotactic Body Radiation Therapy (SBRT) for Intrahepatic Cancer | completed | Phase 2 | 94 | University of Michigan Rogel Cancer CenterOTHER | 1 | Mar 9, 2017 | clinicaltrials |
| NCT01507064 | Neoadjuvant Sorafenib Therapy Prior to Laser Ablation for Hepatocellular Carcinoma(LANEX) | completed | Phase 2 | 40 | Cardarelli HospitalOTHER | 1 | Mar 7, 2017 | clinicaltrials |
| NCT01581307 | Phase II Trial Evaluating OS With Therasphere® + 2nd-Line FOLFOX in Pancreatic Liver Mets | completed | Phase 2 | 9 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT03069508 | Clemizole HCl for Subjects With Hepatocellular Carcinoma | unknown | Phase 2 | 12 | Eiger Group International, Inc.INDUSTRY | 1 | Mar 3, 2017 | clinicaltrials |
| NCT02956772 | Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients | unknown | Phase 2 | 190 | Hunan Provincial People's HospitalOTHER | 1 | Feb 23, 2017 | clinicaltrials |
| NCT00576056 | Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC | terminated | Phase 2 | 19 | University of PittsburghOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT01273662 | Axitinib as Second-line Treatment for Advanced Hepatocellular Carcinoma | completed | Phase 2 | 45 | National Taiwan University HospitalOTHER | 1 | Feb 9, 2017 | clinicaltrials |
| NCT01545804 | Lenalidomide as Second-line Treatment for Advanced Hepatocellular Carcinoma | completed | Phase 2 | 55 | National Taiwan University HospitalOTHER | 1 | Feb 9, 2017 | clinicaltrials |
| NCT03048123 | HAIC Versus TACE for Large and Unresectable Hepatocellular Carcinoma Staged BCLC A/B | completed | Phase 2 | 79 | Sun Yat-sen UniversityOTHER | 1 | Feb 9, 2017 | clinicaltrials |
Data updated 24 days agoSource updated Sep 18, 2017source: clinicaltrials